Pink Sheet reporters and editor discuss BrainStorm’s next steps after withdrawing the NurOwn BLA (:38), NIH director nominee Monica Bertagnolli’s thoughts on drug affordability (8:13), and the US FDA’s effort to ensure long-term follow-up of gene therapy patients (19:41). More On These Topics From The Pink Sheet BrainStorm Eyes New Phase III Trial For NurOwn In Mild ALS Following BLA Withdrawal: https://pink.citeline.com/PS149035/BrainStorm-Eyes-New-Phase-III-Trial-For-NurOwn-In-Mild-ALS-Following-BLA-Withdrawal NIH Nominee Says Americans Deserve ‘Return On Investment’ Via Affordable Meds, But Offers No Implementation Plan: https://pink.citeline.com/PS149040/NIH-Nominee-Says-Americans-Deserve-Return-On-Investment-Via-Affordable-Meds-But-Offers-No-Implementation-Plan Obesity Funding, AI and Clinical Trial Diversity: Where The NIH Director Nominee Stands: https://pink.citeline.com/PS149046/Obesity-Funding-AI-and-Clinical-Trial-Diversity-Where-The-NIH-Director-Nominee-Stands US FDA Struggling With Long-Term Follow-Up Requirements For Gene Therapies: https://pink.citeline.com/PS149041/US-FDA-Struggling-With-Long-Term-Follow-Up-Requirements-For-Gene-Therapies

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.